165 related articles for article (PubMed ID: 20444041)
1. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.
Yancey MF; Merritt DA; Lesman SP; Boucher JF; Michels GM
J Vet Pharmacol Ther; 2010 Apr; 33(2):162-71. PubMed ID: 20444041
[TBL] [Abstract][Full Text] [Related]
2. Distribution, metabolism, and excretion of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in dogs.
Yancey MF; Merritt DA; White JA; Marsh SA; Locuson CW
J Vet Pharmacol Ther; 2010 Apr; 33(2):154-61. PubMed ID: 20444040
[TBL] [Abstract][Full Text] [Related]
3. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM
Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of dirlotapide in the dog.
Merritt DA; Lynch MP; King VL
J Vet Pharmacol Ther; 2007 Aug; 30 Suppl 1():24-32. PubMed ID: 17567512
[TBL] [Abstract][Full Text] [Related]
5. Analytical determination and pharmacokinetics of robenacoxib in the dog.
Jung M; Lees P; Seewald W; King JN
J Vet Pharmacol Ther; 2009 Feb; 32(1):41-8. PubMed ID: 19161454
[TBL] [Abstract][Full Text] [Related]
6. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
London CA; Hannah AL; Zadovoskaya R; Chien MB; Kollias-Baker C; Rosenberg M; Downing S; Post G; Boucher J; Shenoy N; Mendel DB; McMahon G; Cherrington JM
Clin Cancer Res; 2003 Jul; 9(7):2755-68. PubMed ID: 12855656
[TBL] [Abstract][Full Text] [Related]
7. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.
Pryer NK; Lee LB; Zadovaskaya R; Yu X; Sukbuntherng J; Cherrington JM; London CA
Clin Cancer Res; 2003 Nov; 9(15):5729-34. PubMed ID: 14654558
[TBL] [Abstract][Full Text] [Related]
8. Disposition and safety of zonisamide after intravenous and oral single dose and oral multiple dosing in normal hound dogs.
Boothe DM; Perkins J
J Vet Pharmacol Ther; 2008 Dec; 31(6):544-53. PubMed ID: 19000278
[TBL] [Abstract][Full Text] [Related]
9. Cancer drug approved for dogs.
J Am Vet Med Assoc; 2009 Jul; 235(2):139. PubMed ID: 19610240
[No Abstract] [Full Text] [Related]
10. Pharmacokinetics of florfenicol and its metabolite, florfenicol amine, in dogs.
Park BK; Lim JH; Kim MS; Hwang YH; Yun HI
Res Vet Sci; 2008 Feb; 84(1):85-9. PubMed ID: 17570454
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
Yamada Y; Tamura T; Yamamoto N; Shimoyama T; Ueda Y; Murakami H; Kusaba H; Kamiya Y; Saka H; Tanigawara Y; McGovren JP; Natsumeda Y
Cancer Chemother Pharmacol; 2006 Aug; 58(2):173-82. PubMed ID: 16308697
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of the acetylcholinesterase inhibitor 2,2,2-trifluoro-1-(3-trimethylsilylphenyl) ethanone in dog. Potential for transdermal patch delivery.
Dow J; Dulery BD; Hornsperger JM; Di Francesco GF; Keshary P; Haegele KD
Arzneimittelforschung; 1995 Dec; 45(12):1245-52. PubMed ID: 8595078
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
14. [Suitability of the peroral administration of the marker creatinine for the quantitative determination of the glomerular filtration rate (GFR) in dogs].
Hartmann H; Baumgardt T; Höchel J
Berl Munch Tierarztl Wochenschr; 2006; 119(1-2):62-7. PubMed ID: 16450711
[TBL] [Abstract][Full Text] [Related]
15. The pharmacokinetics of mavacoxib, a long-acting COX-2 inhibitor, in young adult laboratory dogs.
Cox SR; Lesman SP; Boucher JF; Krautmann MJ; Hummel BD; Savides M; Marsh S; Fielder A; Stegemann MR
J Vet Pharmacol Ther; 2010 Oct; 33(5):461-70. PubMed ID: 20840390
[TBL] [Abstract][Full Text] [Related]
16. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
[TBL] [Abstract][Full Text] [Related]
17. The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs.
Kukanich B; Lascelles BD; Aman AM; Mealey KL; Papich MG
J Vet Pharmacol Ther; 2005 Oct; 28(5):461-6. PubMed ID: 16207309
[TBL] [Abstract][Full Text] [Related]
18. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
Mita MM; Rowinsky EK; Forero L; Eckhart SG; Izbicka E; Weiss GR; Beeram M; Mita AC; de Bono JS; Tolcher AW; Hammond LA; Simmons P; Berg K; Takimoto C; Patnaik A
Cancer Chemother Pharmacol; 2007 Feb; 59(2):165-74. PubMed ID: 16736151
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus).
Abu-Basha EA; Gehring R; Hantash TM; Al-Shunnaq AF; Idkaidek NM
J Vet Pharmacol Ther; 2009 Jun; 32(3):258-63. PubMed ID: 19646090
[TBL] [Abstract][Full Text] [Related]
20. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]